Sermorelin Explained: The 29-Residue Fragment of Growth Hormone-Releasing Hormone

Growth hormone-releasing hormone runs 44 amino acids long. Decades ago, though, researchers found that its first 29 carry almost the entire message — and that opening segment is sermorelin, written formally as GHRH(1-29). This article is provided for research use only and looks at the chemistry of that fragment: what it is, where it comes from, how it talks to its receptor, and why it disappears from plasma so fast. One caveat up front. Sermorelin is also an international nonproprietary drug name, and research-grade material is not equivalent to the FDA-approved pharmaceutical product of the same name.

What Sermorelin Actually Is

In one line: sermorelin is the 29-amino-acid front end of growth hormone-releasing hormone, reproduced as a standalone peptide. Its chemical profile gives the molecular formula C₁₄₉H₂₄₆N₄₄O₄₂S, a molar mass of roughly 3,357.93 g/mol, and the CAS number 86168-78-7. Its tail is capped with an amide group rather than a free acid — a small structural detail that turns out to matter for how the molecule is recognized.

One well-documented fact is what makes the fragment interesting: it's described as the shortest fully functional fragment of GHRH. Throw away more than a third of the parent hormone, in other words, and the remaining piece still behaves in laboratory models like the whole thing. The rest of this article is really an answer to one question — how can such a large molecule be trimmed so aggressively and still work?

Where the Fragment Comes From

To understand the fragment, start with the parent. Growth hormone-releasing hormone, as its reference entry describes, is a 44-residue peptide made in the arcuate nucleus of the hypothalamus. It's released in pulses and travels through the hypothalamo-hypophyseal portal system — a short, dedicated set of blood vessels — to the anterior pituitary, where it prompts the release of growth hormone.

The trimming story goes back to the early 1980s. Work by Wehrenberg and Ling showed that the first 29 residues of GHRH were as potent in laboratory models as the full 44-residue chain. That result gave the fragment its working name, GRF(1-29), and later its nonproprietary name, sermorelin. If you're researching this compound, that finding is the historical hinge: it established that the "active core" of the hormone lives near the N-terminus rather than spread across the whole sequence.

Reading the 29-Residue Sequence

Here's the chain, residue by residue: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂. Line it up against the parent hormone and you'll see it's an exact copy of GHRH's opening 29 amino acids, as the analogue literature lays out.

A couple of reading conventions help here. Residues are numbered from the N-terminus, so "position 2" means the second amino acid — an alanine — and the "1-29" label simply means residues one through twenty-nine. That trailing "NH₂" is the amide cap mentioned earlier. Thinking structurally rather than by name is a habit worth keeping across peptide chemistry; the same approach applies when you study other short, defined peptide sequences where the exact residue order is the whole story.

Why the Shortest Fragment Still Works

The short answer: receptors read a contact surface, not an entire chain. A peptide hormone doesn't need every one of its residues to fit its receptor — it needs the specific stretch that forms the binding interface. For GHRH, that interface sits within the first 29 residues, which is why the review literature characterizes sermorelin as retaining the full biological activity of the parent hormone in research models.

That's the practical lesson behind "fragment biology." The trailing 15 residues of GHRH aren't useless in the intact hormone, but they're dispensable for the core job of switching on the receptor. Once chemists knew where the active core lived, the door opened to building smaller, easier-to-synthesize molecules around it — which is exactly what happened next.

How the Fragment Talks to the Pituitary

Mechanically, sermorelin works by engaging a single receptor. It binds the growth hormone-releasing hormone receptor (GHRHR), a member of the secretin family of G-protein-coupled receptors encoded on chromosome 7. Once engaged, the receptor signals mainly through the cAMP / protein-kinase-A / CREB pathway, with a secondary contribution from the phospholipase-C (IP3/DAG) route, as the GHRH reference describes.

One more piece of physiology is worth naming, because it's why researchers find GHRH-style molecules interesting in cellular-signaling work. The hormone's output is held in check by somatostatin, its opposing signal; the two are released in alternation, and that's what gives growth hormone its characteristic pulsing rhythm in research models rather than a flat, constant level. This upstream, feedback-regulated mechanism is also what separates fragment-based GHRH peptides from the broader category of growth hormone secretagogue peptides that act through a different receptor entirely.

The Half-Life Problem and Why Chemists Modified the Fragment

The catch with sermorelin is speed. It doesn't last long in plasma — its circulating half-life sits on the order of 10 to 20 minutes, and some sources put the figure under 10. Two things drive that. The kidneys filter the small peptide quickly, and, more specifically, the enzyme dipeptidyl peptidase-4 (DPP-4) clips the bond between residue 2 and the aspartic acid at residue 3. That single cut yields an inactive fragment, as the modified-GRF literature documents.

That vulnerability is precisely what made the fragment a useful scaffold. Swap the alanine at position 2 for its mirror-image form, D-alanine, and you block the DPP-4 cut, letting the molecule persist longer under research conditions. A more aggressive redesign — tetrasubstituted GRF(1-29) — replaces residues 2, 8, 15, and 27 and pushes the laboratory half-life past 30 minutes. The same logic underlies longer-acting relatives such as CJC-1295 and tesamorelin. Substitution is only one tactic, though; chemists also reach for strategies that extend peptide half-life by attaching fatty tails or larger carriers. We see sermorelin, then, less as an endpoint than as the parent design the modern GHRH-analogue family grew out of.

A Regulatory and Historical Footnote

For completeness: sermorelin received U.S. FDA approval in 1997, marketed under the name Geref (NDA 020443). The manufacturer later discontinued production for commercial reasons, and it is no longer an FDA-approved product. We mention this purely as regulatory history — context for the molecule's place in the literature, not a statement about any present-day status or use.

Frequently Asked Questions

What does the "1-29" in sermorelin mean?

It refers to the first 29 amino acids, counting from the N-terminus, of the full 44-residue growth hormone-releasing hormone. Sermorelin is that opening segment reproduced on its own, which is why it is written as GHRH(1-29).

How is sermorelin different from full-length GHRH?

Sermorelin keeps only the first 29 of GHRH's 44 residues and ends in an amide group. Research established that this shorter piece carries the part of the molecule the receptor actually reads, so it behaves like the parent hormone in laboratory models despite missing the final 15 residues.

Why does sermorelin have such a short half-life?

In plasma the enzyme dipeptidyl peptidase-4 quickly clips the bond near the N-terminus, producing an inactive fragment, and the kidneys filter the small peptide rapidly. Together these give a circulating half-life of roughly 10 to 20 minutes.

Is sermorelin the same molecule as CJC-1295 or tesamorelin?

No. Those are structural analogues built on the same GHRH(1-29) scaffold but with amino-acid substitutions or added chemistry that help them resist enzymatic breakdown. Sermorelin is the unmodified fragment itself.

Conclusion

Sermorelin is a textbook case of how a fragment can preserve a hormone's message. By keeping the first 29 residues of GHRH — the stretch that forms the receptor contact surface — it reproduces the parent hormone's signaling behavior in research models while being far easier to synthesize. Its one obvious weakness, a short plasma half-life driven by DPP-4 cleavage, turned out to be the most productive thing about it: the redesigns built to fix it became the modern family of GHRH analogues. For researchers, the fragment is worth knowing not just on its own terms but as the starting point of that lineage. It's also a clean illustration of a principle that recurs across peptide science: identity lives in a defined sequence, and small, deliberate edits to that sequence are how chemists tune a molecule's stability without discarding its core behavior. To go deeper, the related chemistry of half-life extension and receptor selectivity is a natural next read.

For research use only. Not for human or animal consumption of any kind. The information in this article is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The statements made have not been evaluated by the U.S. Food and Drug Administration. These products are NOT FDA APPROVED. Please consult with a licensed healthcare professional before making any decisions regarding your health or research.

Optides LLC is a chemical supplier. Optides LLC is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Optides LLC is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.